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 ABSTRACT 
Objective To describe the factors that contributed to 
successful recruitment of more than 200 000 women to 
the UK Collaborative Trial of Ovarian Cancer Screening, 
one of the largest ever randomised controlled trials. 
Design Descriptive study. 
Setting 13 NHS trusts in England, Wales, and Northern 
Ireland. 
Participants Postmenopausal women aged 50-74; 
exclusion criteria included ovarian malignancy, bilateral 
oophorectomy, increased risk of familial ovarian cancer, 
active non-ovarian malignancy, and participation in 
other ovarian cancer screening trials. 
Main outcome measures Achievement of target 
recruitment, acceptance rates of invitation, and 
recruitment rates. 
Results The trial was set up in 13 centres with 27 
adjoining local health authorities. The coordinating centre 
team was led by one of the senior investigators, who was 
closely involved in planning and day to day trial 
management. Of 1243282 women invited, 23.2% 
(288955) replied that they were eligible and would like to 
participate. Of those sent appointments, 73.6% (205 090) 
attended for recruitment. The acceptance rate varied from 
19% to 33% between trial centres. Measures to ensure 
target recruitment included named coordinating centre 
staff supporting and monitoring each centre, prompt 
identification and resolution of logistic problems, varying 
the volume of invitations by centre, using local non-
attendance rates to determine the size of recruitment 
clinics, and organising large ad hoc clinics supported by 
coordinating centre staff. The trial randomised 202 
638 women in 4.3 years. 
Conclusions Planning and trial management are as 
important as trial design and require equal attention from 
senior investigators. Successful recruitment needs 
constant monitoring by a committed proactive 
management team that is willing to explore individual 
solutions for different centres and use central resources to 
improve local recruitment. Automation of trial processes 
with web based trial management systems is crucial in 
large multicentre randomised controlled trials. 
Recruitment can be further enhanced by using 
information videos and group discussions. 
Trial registration Current Controlled Trials 
ISRCTN22488978. 
INTRODUCTION 
Randomised controlled trials are widely accepted as 
the standard for evaluating healthcare interventions. 
However, only 31% of multicentre randomised con-
trolled trials funded by the UK Medical Research 
Council and the NHS Health Technology Assessment 
Programme that were recruiting between 1994 and 
2002 achieved their original recruitment target.
1
 This 
has important implications for allocation of resources, 
lost opportunity for trials that fail to complete, and loss 
of statistical power for completed trials.
2
 
Although the design and scientific validity of 
randomised controlled trials have been subject to 
intense scrutiny, the management and conduct of these 
trials receive limited attention. Large multicentre 
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randomised controlled trials, like other complex 
organisational ventures, need meticulous management 
if they are to be successful. Many fail to deliver 
because of the lack of a practical professional approach 
to getting the job done.
3
 Furthermore, in randomised 
controlled trials involving screening and prevention, 
having to invite large numbers of potential participants 
is an additional challenge.
4
 
In 2000 expertise accumulated over a decade of 
planning and running ovarian cancer screening trials 
was used to design and set up the UK Collaborative 
Trialof Ovarian Cancer Screening (UKCTOCS;www. 
ukctocs.org.uk).
5-9
 Recruitment of the required target 
of 202 638 women was completed in 2005, making it 
one of the largest ever randomised controlled trials. 
This report describes the approach to planning and 
management that contributed to successful recruit-
ment. 
Fig 1 | Trial design of UK Collaborative Trial of Ovarian 
Cancer Screening. ROCA=risk of ovarian cancer algorithm; 
TVS=transvaginal scan 
METHODS 
The UKCTOCS is a randomised controlled trial 
aiming to assess the impact of screening on mortality 
from ovarian cancer while comprehensively evaluat-
ing performance characteristics of the screening 
strategies, physical and psychological morbidity, 
compliance, and cost. The design involves 200 000 
women randomised to annual screening with serum 
CA 125 or transvaginal ultrasound or no intervention 
(fig 1). The inclusion criteria were women aged 50-
74 and with postmenopausal status; the exclusion 
criteria were bilateral oophorectomy, previous 
ovarian malignancy, increased risk of familial 
ovarian cancer, active non-ovarian malignancy, and 
participation in other ovarian cancer screening trials. 
Postmenopausal women 50-74 years (n=200 000) 
All women followed up through Office for National Statistics 
(England and Wales)/Cancer Registry and Central Services 
Agency (Northern Ireland) as well as postal questionnaires 
Multimodal group 
Annual CA125-ROCA 
(n=50 000) 
Ultrasound group 
Annual TVS 
(n=50 000) 
Control 
group 
(n=100 000) 
Primary end point: 
ovarian cancer 
mortality by 
31 December 2014 
Screening until 31 December 2011; 
7-11 annual screens 
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A senior investigator leads trial management based 
at the coordinating centre. We use a custom built, web 
based trial management system to centralise and 
automate trial processes. We identified NHS trusts 
(trial centres) wishing to participate and set them up in 
a staggered fashion over the course of two years. 
Recruitment started at a trial centre when at least 1500 
local women had accepted the invitation. The launch 
of the trial was accompanied by national media 
coverage. This was followed by local media coverage 
in the form of radio interviews and newspaper articles 
as each centre started recruitment. We briefed the staff 
manning the telephone lines of the patient support 
charities OVACOME and Cancer BACUP and 
provided them with answers to frequently asked 
questions before any publicity. 
Acceptance and recruitment rates at each regional centre 
Regional centre Invited Accepted 
Reported they 
were ineligible* 
Acceptance 
rate† (%) 
No 
randomised 
No of active 
years 
No randomised 
per week 
Manchester 133 584 26 027 8 939 20.9 16 504 3.3 114 
Derby 65 391 19 688 5 093 32.7 14 920 3.0 113 
Cardiff 96 633 23 890 8 754 27.2 16 756 3.4 112 
Portsmouth 95 004 27 462 8 743 31.8 19 182 4.0 109 
East London (Bart’s) 167 419 30 047 10 273 19.1 19 944 4.2 108 
North Wales 73 956 21 299 5 144 31.0 14 326 3.3 99 
North London (Royal Free) 133 572 24 391 6 416 19.2 16 737 3.9 98 
Bristol 75 016 22 863 5 706 33.0 16 550 3.9 96 
Nottingham 77 052 21 906 7 001 31.3 16 779 4.2 91 
Gateshead 109 026 24 635  
22.9 17 323 4.4 89 
Gateshead (PCT invited)‡ 13 000 1 323 
8 882 
Middlesbrough 52 832 13 569 3 274 27.4 9 926 2.6 87 
Belfast (PCT invited)‡ 86 810 16 962 NA 19.5 13 579 3.6 86 
Liverpool (PCT invited)‡ 63 987 14 893 NA 23.3 10 112 4.0 57 
Overall 1 243 282 288 955 NA 24.8 202 638 47.8 96 
Overall excluding 
Gateshead, Belfast and 
Liverpool PCT invited 
1 079 485 255 777 78 225 25.5 NA NA NA 
 
NA=not applicable; PCT=primary care trust. 
*Data incomplete as unknown proportion of ineligible women did not reply. 
†Ineligible women not included in numerator or denominator. 
‡Only eligible women replied owing to manner in which invitations were sent,.  
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Invitation 
We sent information about the trial to all general 
practitioners working in participating primary care 
trusts, after electronic upload of their details into the 
trial management system. We requested electronic 
files containing details of 2000 to 10000 women on a 
regular (usually three monthly) basis from each of the 
participating primary care trusts for upload. We then 
sent women personal invitations and logged replies on 
the trial management system (fig 2). The patient 
support groups OVACOME and Cancer BACUP 
vetted the information for patients, and invitation 
letters contained their contact details. In the course of 
the trial, we revised and simplified the invitation. 
Recruitment and randomisation 
We set the weekly recruitment target at 100 women per 
trial centre. We setup individual profiles comprisingfive 
recruitment clinics a week on the trial management 
system for each trial centre. These consisted of 45 minute 
appointments involving groups of four women. Once 
acceptance was logged, women were automatically 
scheduled into the appointment slots at the centre and sent 
letters. The web browser enabled immediate 
logging of clinic attendance as well as rescheduling of 
appointments by both local and coordinating centre staff. 
At recruitment, women viewed an information video and 
participated in a group discussion. This was immediately 
followed by a one to one discussion in a separate room 
with the research nurse, when women were given the 
opportunity to discuss any private concerns before 
signing consent. The nurse also checked their completed 
datasheet. These documents were sent weekly to the 
coordinating centre, where the trial management system 
automatically confirmed eligibility, 
didrandomisation,scheduledappropriateappointments to 
women allocated to screening, and printed letters to the 
patient and her general practitioner (fig 2). We sent 
requests for more information to women with incomplete 
data and placed “on hold” those whose last menstrual 
period was less than 12 months from date of recruitment. 
The trial management system also classifies screening 
results (ultrasound findings and CA 125 concentrations) 
enteredover the webbrowser, schedules appropriate 
follow-up appointments, and prints all letters to 
individual women. It allows electronic exchange of 
information with the CA 125 analyser in the laboratory 
and with the Office for National Statistics. 
We logged and monitored all complaints centrally. A 
designated person at the coordinating centre wrote to 
each woman directly after investigating the problems 
raised. We explored all suggestions by the women and 
amended trial logistics when appropriate and possible. 
RESULTS 
Between April 2001 and February 2003 we set up the 
trial in 13 NHS trusts (trial centres) in England, Wales, 
and Northern Ireland (table). A variety of logistical 
reasons (lack of space, retirement of potential research 
leads, unwillingness of trusts’ management to commit 
to a 10 year trial, involvement in other ovarian cancer 
screening trials) prevented pre-identified Scottish 
centres from participating. Overall, 27 primary care 
trusts (including local health boards in Wales) with 
3266 general practices were involved. Of these, 22 
(81.5%) primary care trusts provided contact details of 
the women, and we sent invitations as outlined above. 
Five (18.5%) primary care trusts (those adjoining the 
centres at Liverpool, Belfast, and initially Gateshead) 
refused access to the contact details. For these trusts, 
we negotiated an alternative method using “unlinked” 
invitations. This involved sending the standard invita-
tion letter without a recipient’s name to the primary 
care trust in sealed franked envelopes. Trust staff then 
attached address labels and forwarded the letters. 
Women who wished to participate wrote to the 
coordinating centre with their contact details (fig 2). 
We modified trial processes and the trial management 
system to allow manual entry of these data. 
Invitation 
We closely monitored acceptance rates from the start 
and therefore noted within the first six months that 
recruitment was below target. We rapidly introduced 
 
(A) File with personal information of women 
provided by local health authority (HA) 
uploaded on to TMS 
Invitation 
Personal invitations printed and 
posted from coordinating centre 
Control group 
No screening 
Randomisation by TMS 
Replies logged on TMS 
Eligibility confirmed 
TMS schedules appointment at recruitment clinic at appropriate 
centre and prints letters, which are sent out from coordinating centre 
Consent logged and recruitment datasheet scanned into TMS 
Recruitment visit 
Seven minute information video 
Group discussion facilitated by research nurse 
Completion of datasheet 
Five minute interview with research nurse 
when baseline datasheet checked and consent signed 
Blood sample 
(transported overnight to central laboratory) 
Multimodal group 
Screening with serum CA125 
Weekly transfer of documents to coordinating centre 
Invitation 
(B) Invitation letter with no name together with 
datasheet for entry of personal details sent 
in sealed franked envelopes to local HA 
Replies with personal details entered into TMS 
Incomplete datasheet or ineligible 
Women placed “on hold” and 
letters sent for clarification 
Address labels pasted by 
local HA staff and posted 
Ultrasound group 
Screening with transvaginal scan 
Fig 2 | Invitation, recruitment, and randomisation. (A)=recruitment in which primary care 
trusts (PCTs) were allowed access to contact details of women; (B)=recruitment in which 
PCTs did not allow access to contact details of women; TMS=trial management system 
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measures (listed below) to improve rates of acceptance 
of the invitation. Overall, invitations were sent to 
1243282 women, 1 079485 directly by the coordinating 
centre and 163 797 by the primary care trusts adjoining 
the centres at Liverpool, Belfast, and initially 
Gateshead; 288 955 (23.2%) women replied that they 
would like to participate in the trial and were eligible. 
The overall acceptance rate varied between centres 
from 19% in East London to 33% in Bristol (table). 
Recruitment and randomisation 
Between April 2001 and September 2005 205090 
women (73.6% of those who were sent appointments) 
attended for recruitment, and we finally randomised 
202 638 women (fig 3). The number of women 
randomised each month ranged from 117 to 5773 
(median 3955)
10
; the median time from recruitment to 
randomisationwas 12.3 days (25th to 75th centile 8.5 
to 15.5 days). 
A further 10 192 women who accepted the invitation 
were not sent appointments as the recruitment target 
was achieved. With ethics committee approval, we sent 
a letter to thank each woman for her interest in the trial 
and apologise for our inability to offer her a place as the 
target recruitment had been reached. 
Overall recruitment was 96% (range 87-114%) of the 
weekly target of 100 women. Five centres exceeded the 
weekly target (table). The centres using “unlinked 
invitations” had some of the lowest recruitment rates. 
The box details the measures we adopted to ensure 
target recruitment. Ninety eight (0.008%) invited 
women complained about recruitment related problems: 
invitation to trial (32), trial information (28), 
recruitment appointment (17), and randomisation to 
control group (21). 
DISCUSSION 
Our experience highlights the importance of meticulous 
planning and management of trial processes. These are 
as crucial to success as trial design and require equal 
attention from senior investigators. We quickly 
learntthat the key to successful recruitment was 
constant monitoring by a dedicated management team, 
capable of delivering flexible and rapid solutions as 
problems arose. Centralisation and automation of trial 
processes with web based trial management systems 
were crucial. Information videos and group discussions 
facilitated recruitment and helped to maintain quality. 
The revision of the UKCTOCS invitation procedure 
provides an example of the flexibility needed in 
running trials. Although most (81.5%) local health 
authority data controllers allowed access to women’s 
contact details under the research exemption clause of 
the Data Protection Act 1998 (www.informationcom 
missioner.gov.uk), 18.5% (n=5) refused permission. 
We found a compromise to accommodate their 
concerns and revised the entire invitation process, 
including functionality of the trial management system 
and the job description of administrative staff at the 
coordinating centre. Excluding these health authorities 
would have required suspension of the trial in the 
adjoining centres, with a major impact on recruitment 
rates, time, and resources. 
Strengths and weaknesses 
We invited women from participating local health 
authorities’ registers. This is an approach often used 
in the United Kingdom.11 12 Other databases in use 
include electoral rolls, driving licence records, and 
commercially available directories.
13
 The alternative 
strategy is to advertise the trial extensively and let 
participants self refer.
14
 Recently, this has involved 
Google adverts and links to studies on a variety of 
websites.
15
 Women who volunteer to participate in 
research are often more educated and informed than 
the general population.
16-18
 Hence, invitation using 
health authority lists or electoral rolls is thought to 
result in participants who are more representative of 
the general population than those who self refer 
through adverts. Use of health authority lists provides 
additional logistical advantages. Recruitment rates can 
be controlled by varying the volume and frequency of 
mailing invitations, and electronic data transfer from 
health authority files leads to decreased data entry and 
improved accuracy. This is particularly notable with 
regard to NHS numbers, which are essential for cost 
effective follow-up of women through the UK Office 
for National Statistics. In a previous trial, in which 
women self referred, most women did not provide an 
NHS number.
19
 Finally, mass mailing allows accep-
tance rates and their variation between centres to be 
determined. 
Recruitment rates vary with time and between 
centres. Maintaining this at target levels requires 
constant monitoring and individual solutions, as 
problems differ between centres. Support from the 
 
Allocation 
Enrolment 
Contact details of women received as electronic file from PCT and loaded on to TMS (n=1 084 632) 
Women sent invitations by PCTs (n=163 797) 
Control group (n=101 359) 
Attended recruitment (n=205 090) 
Randomisation (n=202 638) 
Accepted (n=288 955) 
33 178 255 777 
Multimodal group (n=50 640) 
Not recruited as target 
reached (n=10 192) 
Women sent invitations from CC (n=1 079 485) 
Excluded (n=2452): 
Did not meet inclusion criteria (n=1402) 
Refused to participate (n=292) 
Other reasons (n=758) 
Ineligible at 
invitation 
(n=78 225) 
Women not sent invitations (n=5147) 
Decided not 
to join 
(n=98 476) 
Ultrasound group (n=50 639) 
Withdrew from 
study (n=73 673) 
Did not 
reply 
(n=647 007) 
Fig 3 | Flow diagram of progress through recruitment phase of UK Collaborative Trial of 
Ovarian Cancer Screening. CC=coordinating centre; PCT=primary care trust; TMS=trial 
management system 
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relevant patients’ support groups is crucial. For trials 
with lower acceptance rates, one solution is to increase 
the volume and frequency of mailing of invitations and 
local media coverage. Mass broadcast (television and 
radio) and print media are “low effort, high yield” 
recruitment strategies.20 21 In the UKCTOCS, as 
participation was limited to invited women, we were 
constantly trying to find the balance between too much 
and too little publicity. To this end, we avoided posters 
and flyers in general practitioners’ surgeries, well 
women clinics, and so on. Such publicity may have 
persuaded more women to take up their invitation. 
In FLEXISIG, the sigmoidoscopy screening trial, the 
involved general practices checked the local authority 
lists and excluded 2% of 375 744 men and women as 
they were deemed ineligible owing to colorectal cancer, 
terminal disease, and so on.
22
 In the UKCTOCS, the 
3266 general practices did no cleaning of lists, as we 
were concerned that this would affect timely mailing of 
invitations, which was crucial to  
maintain target recruitment. Thirty two of 1.2 million 
women invited complained about being contacted. This 
included four women with ovarian cancer out of an 
estimated 587 who would have been invited on the 
basis of national incidences.
23
 Given the small numbers 
excluded in FLEXISIG, the low rate of complaints in 
the UKCTOCS, and the substantial effort required, 
“cleaningup” oflocal authority lists does not seem to be 
necessary. 
The overall acceptance rate was one in four (23%). 
However, the rates varied between different parts of 
the country. The data suggest that in cities such as 
London, Manchester, and Belfast one should expect 
lower acceptance rates in the range of one in five. 
However, in other parts of the country, such as 
Nottingham, Portsmouth, Bristol, and Derby, almost 
one in three women in the 50-74 age group might 
accept an invitation toparticipate in a screeningtrial. 
The varying uptake highlights the importance of 
running pilots at multiple centres. The UKCTOCS 
data are being analysed to see whether acceptance 
rates can be estimated by using age and the postcode 
derived index for multiple deprivation. 
We could not account for undelivered invitations in 
our trial, as the initial invitations were posted in 
envelopes with no return address. In the recent 
FLEXISIG trial, 4% of invitations were undelivered,
12
 
and this is useful in calculating accurate acceptance 
rates. The overall acceptance rate in the UKCTOCS was 
similar to that seen in the colorectal cancer screening 
trial at Dundee and the WISDOM trial involving 
oestrogen use after the menopause.24 25 These rates were 
substantially higher than the 4.3% acceptance rate 
reported after amass mailing of more than 3.4 million in 
the US systolic hypertension (SHEP) trial.
13
 However, 
they were much lower than the 55%achieved in the UK 
FLEXISIG trial. One reason is the way randomisation 
was approached. In the UKCTOCS, we asked women to 
help to test a new screening programme for ovarian 
cancer. We told them that we would need to involve 200 
000 women, half of whom would be screened and half 
would have the usual medical care. In FLEXISIG, 
participants were asked, “If you were invited to have the 
bowel cancer screening test, would you take up the 
offer?” The acceptance rate was based on those who 
answered “yes.”22 This emphasises the importance of 
wording of the invitations, an aspect sometimes 
overlooked in clinical trials. Meta-analysis ofbreast 
screeningtrialsshows that useof direct contact strategies 
involving telephone or any type of personal contact can 
also significantly increase uptake. However, this is only 
feasible in smaller trials, and concerns about the cost 
effectiveness have been expressed.
26
 Another way to 
improve acceptance rates in screening trials is to invite 
people who regularly attend established screening 
programmes such as breast and cervical cancer 
screening, as they are self selected for their belief in 
screening.
27
 In the Million Women Study, 71% of 
women having breast screening returned the study 
questionnaire compared with 53%of all those invited.
28
 
This was not possible in the 
Strategies adopted to facilitate recruitment 
Set-up 
 Custom built trial management system to centralise and automate all trial processes 
such as invitation, logging of replies, scheduling of appointments, confirmation of 
eligibility, randomisation, and printing of letters 
 Webbrowserandhighsecurityencryptionenablingstaffatalllocationstoenterandview 
data and reschedule appointments 
 Specialised software commissioned from the NHS to flagwomen on primary care 
trusts’ registers and allow electronic transfer of their personal and general practice 
details to the coordinating centre in lots of 5000 to 10000 every quarter 
 Trial website (www.ukctocs.org) for use by lay people and health professionals 
Invitation 
 Support of relevant patients’ groups/charities 
 National and local media coverage 
 Mass mailing of invitations from coordinating centre 
 Personal invitation with tear-off reply slip and prepaid return envelopes 
 Accompanying brochure describingthe goals and requirements ofthe trial in simple 
and concise terms 
 Regular monitoring of acceptance rates to establish frequency and volume of mailing 
needed 
Recruitment 
 Ensuring adequate numbers of women have accepted the invitation before 
starting recruitment at a trial centre 
 Increasing appointments in individual recruitment clinics to accommodate low 
attendance 
 Additional large ad hoc clinics staffed by both local and coordinating centre teams 
 Information video at recruitment appointment 
 Interactive group discussions 
Management by coordinating centre 
 Senior investigator involved in day to day running of trial 
 Proactive management team 
 Named coordinating centre member interacting with each trial centre on a daily basis 
 Prompt identification and resolution of logistical problems (staffing, delivery 
of consumables, information technology networking problems, postal strikes) 
 Fortnightly monitoring of targets 
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WHAT IS ALREADY KNOWN ON THIS TOPIC 
In the UK, less than one third ofmulticentre randomised controlled trials achieve their 
original recruitment target 
Limited attention is paid to the management and conduct of these trials 
WHAT THIS STUDY ADDS 
Successful recruitment to trials needs constant monitoring by a committed proactive 
management team, able to rapidly deliver individual solutions as problems arise 
Centralisation and automation of trial processes by use of interactive web based trial 
management systems are crucial in large multicentre randomised controlled trials 
Recruitment can be facilitated by using information videos and group discussions 
UKCTOCS, as these programmes are limited to 
women aged below 65 in the UK. 
In the UKCTOCS, 202 638 women were rando-
mised in 4.3 years, which translates to a randomisation 
rate of 47 125 per year. The only trial to report higher 
rates was the FLEXISIG trial, with a randomisation rate 
of 68 173 per year.
12
 This was achieved by adopting a 
two stage recruitment design; 170483 people who 
agreed to attend bowel cancer screening if invited were 
randomised, and only 40674 allocated to the screen arm 
were recruited.
29
 This design, however, does mean that 
only limited data and no biological samples are 
available in the control group. In addition, recent 
revisions of laws such as the Data Protection Act and 
the Mental Capacity Act might lead to difficulties in 
follow-up through the Office for National Statistics and 
use of data in secondary studies. Nonetheless, postal 
recruitment with attendance at the clinic only for people 
randomisedto the study arm is an attractive design with 
significant savings in terms of time and resources and is 
definitely worth exploring. 
Sophisticated web based trial management systems 
are becoming the norm for multicentre clinical trials.
2930
 
They enable simultaneous data entry from multiple 
sites by using standard web browsers with centralised 
data processing. In large multicentre screening trials 
such as the UKCTOCS, such technology ensures strict 
adherence to the protocol over a long period of time. 
Such solutions can be prohibitively expensive, 
however, especially for individual research groups. A 
move to encourage research and funding organisations 
to combine efforts to produce an open source solution 
for management of trial data is now occurring. This 
would empower a wider variety of people to do trials 
and may encourage more investigators in resource poor 
settings to take part in high standard research.
31
 
A novel feature of the UKCTOCS was the use of an 
information video and group discussion during recruit-
ment. The video ensured that all participants received 
high quality standardised information which was 
sustainable. Research nurses recruiting an average of 
100 women a week find it difficult to deliver the same 
high quality message repeatedly. The video also helped 
with retention of experienced staff by relieving the 
monotony of repeating the same message many times a 
day over four years of recruitment. The group 
discussions often generated queries that helped 
volunteers to arrive at a more educated and informed 
decision than might have been possible if they were 
only seen individually in a busy recruitment clinic. 
One in 6.5 women aged 50-74 in England, Wales, 
and Northern Ireland (total population 8031463) were 
invited to participate in the UKCTOCS.
32
 This is a 
major strength, as it makes extrapolation of the findings 
relevant to people planning randomised controlled trials 
in the UK. However, the population is not wholly 
representative of the UK, as the pre-identified Scottish 
centres were unable to participate. 
Implications of the study 
Running large multicentre trials is challenging. Senior 
investigators need to set aside time to support day to 
day trial management. Centralisation and automation 
of trial processes by use of web based trial 
management systems with high security encryption are 
essential. Information videos and group discussions 
allow sustained delivery of high quality standardised 
information during prolonged recruitment. The over-
riding approach needs to be one that incorporates 
proactive management, flexibility, and individualised 
solutions. Close cooperation and regular 
communication between the coordinating and trial 
centre teams are key to success. 
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